Skip to main content

Peer Review reports

From: Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial

Original Submission
24 Feb 2017 Submitted Original manuscript
24 May 2017 Reviewed Reviewer Report - F.T Awan
4 Jul 2017 Reviewed Reviewer Report - N Hamerschlak
2 Aug 2017 Author responded Author comments - Laura Collett
Resubmission - Version 2
2 Aug 2017 Submitted Manuscript version 2
Publishing
4 Aug 2017 Editorially accepted
22 Aug 2017 Article published 10.1186/s13063-017-2138-6

You can find further information about peer review here.

Back to article page